Suven Life Sciences Limited (NSE:SUVEN)

Market Cap	70.15B +145.5%
Revenue (ttm)	210.45M +216.2%
Net Income	-2.76B
EPS	-12.13
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	781,259
Average Volume	2,243,005
Open	272.00
Previous Close	269.52
Day's Range	259.70 - 274.59
52-Week Range	124.11 - 299.99
Beta	0.71
RSI	75.18
Earnings Date	May 13, 2026

About Suven Life Sciences

Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and internationally. The company engages in drug discovery and development of new chemical entities in central nervous system diseases. Its product candidates include Masupirdine (SUVN-502) for the treatment of Alzheimer disease and neuropsychiatric symptoms; Samelisant (SUVN-G3031), a histamine 3 recepto...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1989
• Employees: 138
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: SUVEN

Financial Performance

In fiscal year 2026, Suven Life Sciences's revenue was 210.45 million, an increase of 216.19% compared to the previous year's 66.56 million. Losses were -2.76 billion, 71.9% more than in 2025.